Huadao Biologics Secures Over RMB 100 Million in Series D+2 Financing Led by Boai Kaixinyuan to Accelerate Affordable CAR-T Therapies

Investment Circle (ID: pedaily2012) October 13th, by reporter, HuaDao CAR-Tcell successfully completed100 million yuanLevelD+2 Round of Financing,This round of financing was led byBo'ai Xinkaiyuan led the investment round, with participation from Jinghu Capital, Wuhan He'er, Zhejiang Shenchang, Ningbo Zibei, and other institutions and investors.。This round of financing will be mainly used to accelerate the research, development, and industrialization process of affordable cell therapies, further promoting the commercial production and application of HuaDao CAR-Tcell's innovative, self-developed technology platform for the entire cell drug industry chain at its first-phase intelligent manufacturing industrial base (Shanghai) for CAR-T cell drug production.

HuaDao CAR-Tcell is a biopharmaceutical company specializing in cellular immunotherapy, with a particular focus on the technical development and innovation of the entire cell drug industry chain. It was established in September 2017 in Zhangjiang, Shanghai, and relocated to Songjiang, Shanghai in 2020, within the National Songjiang Economic and Technological Development Zone, the main hub of "Songjiang Creation."

The company adheres to a dual innovation path of "cell drug R&D + key equipment and technology breakthroughs for industrialization" with independent intellectual property rights. After seven years of development, it has overcome key production equipment for cell (CAR-T) preparation, supporting single-use consumables, intelligent cell (CAR-T) liquid nitrogen cold chain transportation, and other critical equipment and bottleneck technologies for the industrialization of cell (CAR-T).

HuaDao CAR-Tcell Chairman and General Manager Xuejun Yu stated:We would like to express our heartfelt gratitude to all partners for their trust in HuaDao CAR-Tcell's consistently accessible cell drug platform technology. Let us jointly look forward to the unmanned intelligent production management system to be showcased in the first phase of HuaDao CAR-Tcell's intelligent manufacturing industrialization base (Shanghai) construction project for CAR-T cell drugs. This system will revolutionarily disrupt the production and manufacturing costs of personalized CAR-T cell drugs, fulfilling the historical mission of achieving people's health and well-being through innovation and development in the biopharmaceuticals industry. We also sincerely invite more partners to follow the company’s subsequent pre-IPO financing round and participate in supporting HuaDao CAR-Tcell’s bold step onto the STAR Market with its mission of "China-made alternatives, affordable and accessible."

Zhang Junzheng, Chairman of Bo'ai Xinkaiyuan, stated: Currently, HuaDao CAR-Tcell's "Hua Mountain Path" is about to stride into the center stage of the cell drug industrialization. As the saying goes, "Freshly sharpened, pioneering achievements, and a long-lasting source," BioVision hopes that more partners will actively participate in HuaDao CAR-Tcell's pre-IPO financing round. This aims to improve the entire industrial chain system of cell drugs—"R&D + Clinical Trials + Manufacturing + Application." It will also accelerate the open-source sharing of accessible cell drug industry technology platforms, stimulate and drive the upstream and downstream aggregation of China’s cell drug industry chain and supply chain, set a clear direction for innovation, and pave the way for the future.

Wen Pin, founding partner of Mirror Lake Capital, said:Mirror Lake Capital has been closely monitoring the cell therapy industry, which has broad prospects. This time, by chance, we got to know HuaDao CAR-Tcell, a company that has been focusing on research and development with little media exposure. Their commitment to "persisting in technological innovation across the entire industrial chain and making cell drugs affordable for ordinary people" has shown us the potential strength and possible solution for breaking new ground in China's cell therapy industry. Even good wine goes to waste if it’s hidden in a deep alley. Mirror Lake Capital will take this investment as a strategic opportunity to continuously support HuaDao CAR-Tcell along its journey.

Zhejiang Shenchang representative Chai Xupeng stated:We are committed to bringing cutting-edge scientific and technological achievements into every household, addressing unmet clinical needs and solving unresolved clinical challenges with advanced breakthroughs. The path of HuaDao CAR-Tcell's accessible cell drug R&D and transformation platform aligns perfectly with our mission, further strengthening our confidence in the road of integrated innovation across the entire industry chain of "production, academia, research, medicine, and investment" to create value for society.

Zhang Huan, General Manager of Ningbo Zibei, said:"Reducing the sky-high price of million-dollar drugs" is something many companies initially wanted to achieve, but most gave up in the end. I’m very pleased that HuaDao CAR-Tcell has remained true to its original mission, doing the most with the least, truly practicing "relying on industrial technological innovation to reduce costs to the extreme." I’m looking forward to seeing HuaDao in 2026 and 2027, as it brings "affordable and accessible cell drugs for ordinary people" to benefit people around the world.